Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026

HSDT vs NUWE: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

HSDT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

HSDT Overall Winner 6-Pillar Tally: HSDT 3 – 2 NUWE (1 Tie) Matrix Metrics: HSDT 7 – 2 NUWE

As of Nov 19, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Nuwellis, Inc. (NUWE) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSDT carries a Unified Composite Score of 59.0/100 (HOLD) at $1.66 (N/M Forward P/E, -1557.5% operating margin), whereas NUWE carries 37.8/100 (SELL) at $3.81 (N/M Forward P/E, -142.9% operating margin).

  • Technical & Structure Timing Caution: HSDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.4); meanwhile NUWE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About HSDT vs NUWE
HSDT NASDAQ Head-to-Head Winner
Solana Company Class A Common Stock (DE)
Electromedical & Electrotherapeutic Apparatus
$1.66
+1.84% 1D
Market Cap $103.1M
TTM Revenue $272M
Forward P/E N/M
Beta / 30D Vol 2.20β · 55% Vol
Unified Composite Score
59.0 / 100 HOLD
Tech 60.0 Fund 53.0 Flow 58.0 Mom 55.0
Weinstein Technical Phase Markdown · Sell / avoid
Price below a falling SMA50 (slope -2.0%), weak momentum, RSI 29
RSI-14: 29.4 · SMA20: $1.96 · SMA50: $2.31
NUWE NASDAQ
Nuwellis, Inc. Common Stock
Electromedical & Electrotherapeutic Apparatus
$3.81
-2.06% 1D
Market Cap $2.1M
TTM Revenue $9.0M
Forward P/E N/M
Beta / 30D Vol -8.47β · 4990% Vol
Unified Composite Score
37.8 / 100 SELL
Tech 15.0 Fund 33.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (173.2% over 20 days), RSI 51
RSI-14: 51.1 · SMA20: $4.54 · SMA50: $2.24

6-Pillar Scorecard Institutional Category Breakdown (HSDT 3 – 2 NUWE)

Columns: Metric · HSDT · NUWE
1. Valuation Multiples HSDT
Forward P/E N/M N/M
Trailing P/E 0.0x N/M
PEG Ratio N/M N/M
EV / Revenue 0.4x N/M
2. Growth & Scale HSDT
Revenue Growth (YoY) +382.1% +14.1%
Earnings Growth (YoY) +0.0% -99.2%
TTM Revenue (USD) $272M $9.0M
Market Cap $103.1M $2.1M
3. Profitability & Quality HSDT
Gross Margin 92.8% 69.7%
Operating Margin -1557.5% -142.9%
Net Profit Margin 2040.4% -125.6%
Return on Equity (ROE) 52.8% -609.4%
4. Balance Sheet & Cash Flow NUWE
Cash Generation (TTM) -$4.22B EBITDA -$13M EBITDA
Cash Flow Margin N/A -141.2% EBITDA Mgn
Net Cash / Leverage $4.38 Book/Sh · 52.8% ROE $3.7M Net Cash
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning NUWE
Options Structure Phase BREAKDOWN UNCLASSIFIED
Current IV / %ile 540.7% (85th %ile) N/A (N/A)
Put/Call OI Skew 7.50x (Put-Skewed) N/A
OBV Trend / Tech Phase DISTRIBUTION · Markdown NEUTRAL · Markup
6. R&D & Supply-Chain Moat Tie
OpEx & R&D Intensity N/A N/A
90D R&D Disclosures 0 papers 0 papers
Competitive Moat High-Margin Pricing Power Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Asset Management Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: HSDT (7) vs NUWE (2)
Institutional Metric HSDT NUWE Criterion Row Edge
Market Capitalization
Scale
$103.1M $2.1M Larger Scale HSDT
Trailing P/E Ratio
Valuation
0.0x N/M Lower Multiple HSDT
Forward P/E Ratio
Valuation
N/M N/M Lower Multiple Tie
Revenue Growth (YoY)
Growth
+382.1% +14.1% Higher Growth HSDT
Operating Margin (TTM)
Profitability
-1557.5% -142.9% Higher Margin NUWE
Net Profit Margin
Profitability
2040.4% -125.6% Higher Margin HSDT
Return on Equity (ROE)
Capital Efficiency
52.8% -609.4% Higher ROE HSDT
52-Week Range Position
Momentum
15% ($1–$4) 53% ($0–$7) Stronger Trend NUWE
Beta / 30D Volatility
Risk Regime
2.20β · 55% Vol -8.47β · 4990% Vol Lower Realized Risk HSDT
Unified Institutional Score
Composite Signal
59.0 / 100 (HOLD) 37.8 / 100 (SELL) Higher Composite HSDT
Trailing 12M Revenue (USD)
Operating Scale
$272M $9.0M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
92.8% 69.7% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
N/M PEG · 0.4x EV/Rev N/M PEG · N/M EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$4.22B EBITDA ($4.38 Book/Sh · 52.8% ROE) -$13M EBITDA ($3.7M Net Cash) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon NUWE +660.1 pp
HSDT: -29.66% · NUWE: +630.44%
3M Horizon NUWE +249.4 pp
HSDT: -20.95% · NUWE: +228.45%
6M Horizon NUWE +312.0 pp
HSDT: -29.66% · NUWE: +282.34%
1Y Horizon NUWE +119.94 pp
HSDT: -58.5% · NUWE: +61.44%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period HSDT Revenue NUWE Revenue HSDT Op. Margin NUWE Op. Margin Margin Leader
FY2018 $0M $0M -5580.5% -340.9% NUWE
FY2019 $0M $10M -1604.0% -328.5% NUWE
FY2020 $0M $10M -2176.4% -228.8% NUWE
FY2021 $0M $10M -3679.9% -246.5% NUWE
FY2022 $0M $10M -1994.3% -201.0% NUWE
FY2023 $0M $10M -2054.2% -198.9% NUWE
FY2024 $0M $10M -2673.7% -125.7% NUWE
FY2025 $0M $10M -44496.4% -134.3% NUWE

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
HSDT BREAKDOWN
42d in phase · OBV DISTRIBUTION
Current IV 540.7%
IV Percentile 85th %ile
Put/Call OI Skew 7.50x (Put-Skewed)
IV Regime Extreme (>80th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow DISTRIBUTION
Exact HSDT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
NUWE UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV N/A
IV Percentile N/A
Put/Call OI Skew N/A
IV Regime Unclassified
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact NUWE Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
HSDT Moat Profile High-Margin Pricing Power Moat
Asset Management Operator
Competes within the Asset Management value chain with $103.1M market capitalization and -1557.5% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published
NUWE Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $2.1M market capitalization and -142.9% operating margin.
OpEx & R&D Reinvestment N/A
90D Engineering Disclosures 0 Published

Investor FAQ HSDT vs NUWE Key Questions & Quantitative Answers

As of Nov 19, 2026, Solana Company (HSDT) is the stronger overall head-to-head candidate over Nuwellis, Inc. (NUWE) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). HSDT carries a Unified Composite Score of 59.0/100 (HOLD) at $1.66 (N/M Forward P/E, -1557.5% operating margin), whereas NUWE carries 37.8/100 (SELL) at $3.81 (N/M Forward P/E, -142.9% operating margin). Technical & Structure Timing Caution: HSDT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 29.4); meanwhile NUWE trades in a Markup technical trend (UNCLASSIFIED options phase, RSI 51.1). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

HSDT leads the Growth & Scale pillar: HSDT posts +382.1% YoY revenue growth and +0.0% YoY earnings growth on $272M TTM revenue (92.8% gross margin, -1557.5% operating margin), compared with NUWE at +14.1% YoY revenue growth and -99.2% YoY earnings growth on $9.0M TTM revenue (69.7% gross margin, -142.9% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), HSDT cumulative revenue shifted N/A while NUWE shifted +0.0%. In operating R&D and SG&A reinvestment, HSDT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for NUWE.

HSDT screens cheaper on headline valuation multiples. HSDT trades at N/M Forward P/E, 0.0x Trailing P/E, N/M PEG, and 0.4x EV/Revenue (unreported EBITDA margin), whereas NUWE trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (-141.2% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against HSDT (52.8% ROE) versus NUWE (-609.4% ROE) capital efficiency.

In options market volatility and institutional positioning, HSDT carries 540.7% implied volatility (85th %ile, Extreme (>80th %ile)), a 7.50x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a BREAKDOWN options structure phase (2.20β · 55% Vol realized risk). By comparison, NUWE carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-8.47β · 4990% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.